* Concerta® is a registered trademark of Janssen-Cilag Ltd.
±Matoride is a registered trademark of Sandoz
1 Xaggitin XL prolonged release methylphenidate tables Summary of Product Characteristics.
2 Data on file: bioequivalence studies
3 Drug Tariff May 2017 (England and Wales)
4 NHS Drug tariff guidance notes
† Based on the category C reimbursement price for generic prolonged-release methylphenidate tablets (NHS Drug Tariff February 2017 England and Wales
Bioavailability over time under fasting conditions2
The pharmacokinetic profiles of Xaggitin® XL and Concerta® XL demonstrate a matched biphasic release of methylphenidate over time, confirmed with four single-dose multiphasic bioequivalence studies2
Ethypharm UK will guarantee that the price of Xaggitin® XL will not increase, subject to there being no material change to the PPRS or Category C of the Drug Tariff, outside the control of Ethypharm. 4